WORKED EXAMPLE · PUBLIC RECORDS
EQ101: what the published record answers, and what it doesn’t
The study gives a reason to read further, not a reason to assume EQ101 is available. The next question is who can open the records and discuss rights.
Sources checked November 21, 2026. Study NCT05589610. Alopecia areata is autoimmune hair loss, not ordinary age-related hair thinning.
Read the numbers in the right order
Equillium’s June 2024 public results announcement describes an open-label Phase 2 study. Of 36 people enrolled, 25 completed it. Five of those 25 completers had hair loss over no more than 20% of the scalp at week 24. That is a result in the completer group, not five out of an otherwise fully measured group of 36. There was no comparison group.
The headline result was about hair loss. In the registry results, the primary outcome tracked treatment-emergent adverse events. Neither the sponsor’s hair-loss figure nor the fact that adverse events were tracked establishes that EQ101 works or is safe.
Separate the company’s old reason from today’s situation
The 2024 annual report said Equillium paused development while seeking funding or a partner. Its September 2026 quarterly filing focuses on other programs. That silence is not proof the rights are available, unavailable, or still controlled by the same party.
What would change the call?
Hold. Equillium is the first company to ask, not a verified current rights holder. Ask whether a licensing discussion is open and whether it can share the full human study report. Record who answered, what they can grant or share, and the date. If the rights and data are controlled separately, record both.
Check a different trial Read how we handle sources and corrections